Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Equity Average (2016 - 2025)

Syndax Pharmaceuticals has reported Equity Average over the past 10 years, most recently at $90.0 million for Q4 2025.

  • Quarterly results put Equity Average at $90.0 million for Q4 2025, down 72.49% from a year ago — trailing twelve months through Dec 2025 was $90.0 million (down 72.49% YoY), and the annual figure for FY2025 was $176.4 million, down 58.12%.
  • Equity Average for Q4 2025 was $90.0 million at Syndax Pharmaceuticals, down from $136.4 million in the prior quarter.
  • Over the last five years, Equity Average for SNDX hit a ceiling of $523.0 million in Q1 2024 and a floor of $90.0 million in Q4 2025.
  • Median Equity Average over the past 5 years was $359.1 million (2022), compared with a mean of $328.4 million.
  • Biggest five-year swings in Equity Average: surged 464.44% in 2021 and later plummeted 72.49% in 2025.
  • Syndax Pharmaceuticals' Equity Average stood at $303.7 million in 2021, then skyrocketed by 32.63% to $402.8 million in 2022, then increased by 13.39% to $456.7 million in 2023, then fell by 28.34% to $327.3 million in 2024, then plummeted by 72.49% to $90.0 million in 2025.
  • The last three reported values for Equity Average were $90.0 million (Q4 2025), $136.4 million (Q3 2025), and $186.2 million (Q2 2025) per Business Quant data.